Korro Bio (KRRO)
NASDAQ:KRRO
Want to see KRRO full AI Analyst Report?
KRRO Stock Chart & Stats
$14.39
-$1.03(-2.68%)
At close: 4:00 PM EST
$14.39
-$1.03(-2.68%)
Day’s Range― - ―
52-Week Range$5.20 - $55.89
Previous CloseN/A
Volume28.02K
Average Volume (3M)734.66K
Market Cap
$185.91M
Enterprise Value$142.36M
Total Cash (Recent Filing)$75.16M
Total Debt (Recent Filing)$43.49M
Price to Earnings (P/E)―
Beta2.60
Next Earnings
May 19, 2026EPS Estimate
-1.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.33
Shares Outstanding14,422,571
10 Day Avg. Volume1,808,258
30 Day Avg. Volume734,659
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.46
Price to Sales (P/S)11.77
P/FCF Ratio-0.95
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue22.27
Enterprise Value/Gross Profit24.79
Enterprise Value/Ebitda-1.74
Forecast
1Y Price Target
$19.75Price Target Upside37.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-6.5
Revenue Forecast (FY)$2.20M
Bulls Say, Bears Say
Bulls Say
Platform Validation And Pipeline DiversificationAdvancing KRRO-121 as a second, independently risk‑mitigated asset supports the OPERA RNA editing platform's broader utility and prompted analyst upgrades that reflect renewed confidence in the company's development strategy.
Preclinical Efficacy And Safety ProfileAnimal studies, including non-human primates, demonstrated repeatable ammonia reductions, highly liver‑selective distribution, minimal off‑target exposure, and no meaningful changes in key laboratory markers, supporting translational prospects for human testing.
Therapeutic MechanismKRRO-121 is designed to stabilize glutamine synthetase to create a compensatory metabolic pathway, and preclinical models showed ammonia reductions that suggest potential for continuous liver-based ammonia control with infrequent subcutaneous dosing compared with short-acting scavengers.
Bears Say
Delivery And Clinical Execution RiskDisappointing clinical outcomes linked to a lipid nanoparticle delivery component, together with ex‑vivo evidence that the particle behaves differently in patients, raise material concerns about delivery efficacy, human exposure, and first‑in‑human dose durability.
Investor Confidence And Execution UncertaintyNegative results from a prior RNA editing program triggered a substantial selloff and weakened investor confidence, underscoring the risk that additional setbacks or regulatory hurdles could amplify valuation pressure.
Partnership Revenue ImpactA pause in the collaboration with Novo Nordisk reduced collaboration revenue and could slow partnered development efforts, increasing dependence on internal milestones to sustain progress.
Korro Bio News
KRRO FAQ
What was Korro Bio’s price range in the past 12 months?
Korro Bio lowest stock price was $5.20 and its highest was $55.89 in the past 12 months.
What is Korro Bio’s market cap?
Korro Bio’s market cap is $185.91M.
When is Korro Bio’s upcoming earnings report date?
Korro Bio’s upcoming earnings report date is May 19, 2026 which is in 19 days.
How were Korro Bio’s earnings last quarter?
Korro Bio released its earnings results on Mar 12, 2026. The company reported -$5.33 earnings per share for the quarter, missing the consensus estimate of -$2.07 by -$3.26.
Is Korro Bio overvalued?
According to Wall Street analysts Korro Bio’s price is currently Undervalued.
Does Korro Bio pay dividends?
Korro Bio does not currently pay dividends.
What is Korro Bio’s EPS estimate?
Korro Bio’s EPS estimate is -1.73.
How many shares outstanding does Korro Bio have?
Korro Bio has 14,422,571 shares outstanding.
What happened to Korro Bio’s price movement after its last earnings report?
Korro Bio reported an EPS of -$5.33 in its last earnings report, missing expectations of -$2.07. Following the earnings report the stock price went up 11.304%.
Which hedge fund is a major shareholder of Korro Bio?
Currently, no hedge funds are holding shares in KRRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Korro Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (37.25% Upside)
$19.75 (37.25% Upside)
Hedge Fund Trend
Decreased
By 681.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-88.72%
12-Months-Change
Fundamentals
Return on Equity
-115.95%
Trailing 12-Months
Asset Growth
-48.86%
Trailing 12-Months
Company Description
Korro Bio
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
KRRO Stock 12 Month Forecast
Average Price Target
$19.75
▲(37.25% Upside)
Technical Analysis
Assembly Biosciences
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Aura Biosciences Inc
―